<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">N9VYWNbTsN4bnR8sKWKdQKn</article-id>
      <article-id pub-id-type="other">00009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009001000009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09300409</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009001000009</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Estudo da reatividade vascular em portadores de HIV com e sem uso de inibidor de protease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Teixeira</surname>
            <given-names>Hamilton Nenrod Pereira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mesquita</surname>
            <given-names>Evandro Tinoco</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>M&#225;rio Luiz</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bazin</surname>
            <given-names>Anna Ricordi</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mesquita</surname>
            <given-names>Cl&#225;udio Tinoco</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Teixeira</surname>
            <given-names>Manuel Pereira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pellegrini</surname>
            <given-names>Rafael da Cunha</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>N&#243;brega</surname>
            <given-names>Antonio Claudio Lucas da</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Niter&#243;i</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal Fluminense</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>10</month>
        <year>2009</year>
      </pub-date>
      <volume>93</volume>
      <issue>4</issue>
      <fpage>367</fpage>
      <lpage>373</lpage>
      <history>
        <date date-type="rev-recd">
          <day>09</day>
          <month>11</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>10</day>
          <month>08</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>12</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: Considerando o alto n&#250;mero de pacientes infectados por HIV em uso de antirretrovirais, evoluindo com altera&#231;&#227;o da fun&#231;&#227;o endotelial e aterotrombose, levando ao alto custo m&#233;dico social, &#233; importante identificar mecanismos fisiopatol&#243;gicos envolvidos com a fun&#231;&#227;o endotelial em portadores de HIV, para que, precocemente, possamos intervir e evitar a progress&#227;o da doen&#231;a. OBJETIVO: Avaliar a fun&#231;&#227;o endotelial pela vasodilata&#231;&#227;o endot&#233;lio dependente e independente em pacientes HIV positivo e em grupo controle. M&#201;TODOS: O estudo avaliou 27 pacientes HIV positivo e 16 do grupo controle. A avalia&#231;&#227;o da fun&#231;&#227;o endotelial foi realizada por meio da vasodilata&#231;&#227;o da art&#233;ria braquial endot&#233;lio dependente (hiperemia reativa) e independente (nitroglicerina SL). RESULTADOS: Pacientes HIV positivo em uso de inibidor de protease (IP) apresentaram vasodilata&#231;&#227;o endot&#233;lio independente significativamente menor que os subgrupos HIV negativo (p = 0,020) e HIV positivo sem uso de IP (p = 0,034). A varia&#231;&#227;o do di&#226;metro da art&#233;ria braquial durante hiperemia reativa n&#227;o apresentou signific&#226;ncia estat&#237;stica em qualquer subgrupo. A an&#225;lise de regress&#227;o linear m&#250;ltipla mostrou que apenas o IP estava associado ao delta relativo da reatividade braquial pelo vasodilatador, nos pacientes HIV positivo, aos 60 e 90 segundos. CONCLUS&#195;O: Os pacientes HIV positivo em uso de IP apresentam disfun&#231;&#227;o endot&#233;lio independente quando comparados a pacientes HIV positivo que n&#227;o fazem uso de IP e a um grupo controle.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Endot&#233;lio vascular</kwd>
        <kwd>HIV</kwd>
        <kwd>inibidores de proteases</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>24</day>
        <month>11</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> DUPLEX-SCAN/ULTRASSONOGRAFIA VASCULAR DOPPLER</p>
    <p>
      <bold>Estudo da reatividade vascular em portadores de HIV com e sem uso de inibidor de protease</bold>
    </p>
    <p>
      <bold>Hamilton Nenrod Pereira Teixeira; Evandro Tinoco Mesquita; M&#225;rio Luiz Ribeiro; Anna Ricordi Bazin; Cl&#225;udio Tinoco Mesquita; Manuel Pereira Teixeira; Rafael da Cunha Pellegrini; Antonio Claudio Lucas da N&#243;brega</bold>
    </p>
    <p>Universidade Federal Fluminense (UFF), Niter&#243;i, RJ - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO: </bold> Considerando o alto n&#250;mero de pacientes infectados por HIV em uso de antirretrovirais, evoluindo com altera&#231;&#227;o da fun&#231;&#227;o endotelial e aterotrombose, levando ao alto custo m&#233;dico social, &#233; importante identificar mecanismos fisiopatol&#243;gicos envolvidos com a fun&#231;&#227;o endotelial em portadores de HIV, para que, precocemente, possamos intervir e evitar a progress&#227;o da doen&#231;a. </p>
    <p><bold>OBJETIVO:</bold> Avaliar a fun&#231;&#227;o endotelial pela vasodilata&#231;&#227;o endot&#233;lio dependente e independente em pacientes HIV positivo e em grupo controle. </p>
    <p><bold>M&#201;TODOS:</bold> O estudo avaliou 27 pacientes HIV positivo e 16 do grupo controle. A avalia&#231;&#227;o da fun&#231;&#227;o endotelial foi realizada por meio da vasodilata&#231;&#227;o da art&#233;ria braquial endot&#233;lio dependente (hiperemia reativa) e independente (nitroglicerina SL). </p>
    <p><bold>RESULTADOS:</bold> Pacientes HIV positivo em uso de inibidor de protease (IP) apresentaram vasodilata&#231;&#227;o endot&#233;lio independente significativamente menor que os subgrupos HIV negativo (p = 0,020) e HIV positivo sem uso de IP (p = 0,034). A varia&#231;&#227;o do di&#226;metro da art&#233;ria braquial durante hiperemia reativa n&#227;o apresentou signific&#226;ncia estat&#237;stica em qualquer subgrupo. A an&#225;lise de regress&#227;o linear m&#250;ltipla mostrou que apenas o IP estava associado ao delta relativo da reatividade braquial pelo vasodilatador, nos pacientes HIV positivo, aos 60 e 90 segundos. </p>
    <p><bold>CONCLUS&#195;O: </bold> Os pacientes HIV positivo em uso de IP apresentam disfun&#231;&#227;o endot&#233;lio independente quando comparados a pacientes HIV positivo que n&#227;o fazem uso de IP e a um grupo controle. </p>
    <p><bold>Palavras-chave: </bold> Endot&#233;lio vascular/fisiopatologia, HIV, inibidores de proteases.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Ao final da d&#233;cada de 80, os pacientes infectados pelo V&#237;rus da Imunodefici&#234;ncia humana (HIV) tinham pequena sobrevida<sup>1</sup>. Em contraste, no in&#237;cio do s&#233;culo XXI, h&#225; melhora da expectativa de vida desses pacientes, devido ao impacto da terapia com novas drogas antirretrovirais (do ingl&#234;s, <italic>Highly Active Anti-retroviral Therapy</italic> - HAART)<sup>2,3</sup>. A HAART melhora o progn&#243;stico dos pacientes infectados pelo v&#237;rus HIV, diminuindo a incid&#234;ncia de infec&#231;&#245;es oportunistas, hospitaliza&#231;&#227;o e mortalidade<sup>4</sup>.</p>
    <p>V&#225;rios fatores contribuem para o aumento do risco de doen&#231;a cardiovascular nos portadores de HIV, tais como a inflama&#231;&#227;o cr&#244;nica devido &#224; infec&#231;&#227;o pelo v&#237;rus, a a&#231;&#227;o dos IPs e a intera&#231;&#227;o com fatores de risco tradicionais<sup>5</sup>. Portanto, a predisposi&#231;&#227;o &#224; aterosclerose resulta da exposi&#231;&#227;o cumulativa ao v&#237;rus e de altera&#231;&#245;es metab&#243;licas secund&#225;rias ao uso de IP, determinando um perfil metab&#243;lico desfavor&#225;vel, caracterizado por hipertrigliceridemia, HDL-c baixo e resist&#234;ncia insul&#237;nica que ocorre em 25% a 60% dos pacientes<sup>6</sup>.</p>
    <p>Os IPs s&#227;o atualmente considerados fator de risco cardiovascular independente e est&#227;o associados ao aumento de 26% da taxa de infarto agudo do mioc&#225;rdio (IAM) por ano de exposi&#231;&#227;o, em pacientes que iniciaram o tratamento h&#225;, pelo menos, quatro anos<sup>7</sup>. Em 1998, foram demonstrados os primeiros casos de doen&#231;a coronariana prematura em dois jovens HIV positivo em uso de IP<sup>8</sup>.</p>
    <p>V&#225;rios estudos demonstram que a disfun&#231;&#227;o endotelial ocorre nos est&#225;gios iniciais da resist&#234;ncia insul&#237;nica presente em pacientes em uso de HAART. A hipoadiponectinemia &#233; um dos respons&#225;veis pela lipodistrofia e pelo dist&#250;rbio metab&#243;lico nos pacientes HIV positivo em uso de IP<sup>9,10</sup>. A disfun&#231;&#227;o endotelial &#233; um evento prematuro no desencadeamento das les&#245;es ateroscler&#243;ticas e pode ser facilmente medida de maneira n&#227;o invasiva pela avalia&#231;&#227;o de ultrassom do fluxo da art&#233;ria braquial<sup>11</sup>. Os mecanismos que levam &#224; disfun&#231;&#227;o endotelial nos pacientes HIV positivo em uso de IP ainda n&#227;o est&#227;o totalmente explicados.</p>
    <p>O objetivo deste estudo &#233; avaliar a fun&#231;&#227;o do endot&#233;lio dependente e independente, por m&#233;todo n&#227;o invasivo da dilata&#231;&#227;o fluxo mediada da art&#233;ria braquial (DILA) por meio da ultrassonografia em pacientes HIV positivo com e sem uso de HAART. Comparamos a DILA em tr&#234;s grupos: HIV infectado sem uso de IP, HIV infectado em uso de IP e controles sem HIV.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>O estudo avaliou 43 pacientes com idades entre 20 e 55 anos, de ambos os sexos, que foram submetidos &#224; avalia&#231;&#227;o cl&#237;nico-laboratorial e ao protocolo de um dia para avalia&#231;&#227;o n&#227;o invasiva da fun&#231;&#227;o endotelial por meio da ultrassonografia.</p>
    <p>O grupo l envolveu 15 pacientes HIV positivo em uso cr&#244;nico de IP (h&#225; dois anos) e o grupo II com 12 pacientes HIV positivo sem uso pr&#233;vio de IP. Um grupo controle de 16 volunt&#225;rios de ambos os sexos e HIV negativo tamb&#233;m foi avaliado.</p>
    <p>Foram usados como crit&#233;rios de exclus&#227;o a presen&#231;a de doen&#231;a arterial coronariana, cerebrovascular ou vascular perif&#233;rica, o uso de anticoncepcionais, a disfun&#231;&#227;o ventricular (fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo &lt; 45% pelo m&#233;todo de Simpson), a creatinina plasm&#225;tica acima de 1,5 mg e as doen&#231;as neopl&#225;sicas e da tire&#243;ide.</p>
    <p>Dados da hist&#243;ria cl&#237;nica do paciente inclu&#237;ram idade, sexo, peso (kg), &#237;ndice de massa corporal (IMC), tabagismo e est&#225;gio da infec&#231;&#227;o do HIV, de acordo com o CD4 (linf&#243;citos T Helper).</p>
    <p>
      <bold>Estudo da fun&#231;&#227;o endotelial - protocolo</bold>
    </p>
    <p>A t&#233;cnica utilizada foi a descrita por Celermajer e cols. e &#233; recomendada pela <italic>International Brachial Artery Reactivity Task Force</italic><sup>12</sup>.</p>
    <p>O paciente mant&#233;m jejum por, no m&#237;nimo, oito horas, devendo evitar a pr&#225;tica de exerc&#237;cios f&#237;sicos na v&#233;spera do exame e o uso de subst&#226;ncias que interfiram na vasodilata&#231;&#227;o arterial, como a cafe&#237;na, a vitamina C e o cigarro. Para as mulheres, a avalia&#231;&#227;o &#233; realizada fora do per&#237;odo menstrual.</p>
    <p>O paciente &#233; colocado em posi&#231;&#227;o supina, com o bra&#231;o confort&#225;vel apoiado em um suporte apropriado. Ent&#227;o, a imagem da art&#233;ria braquial &#233; obtida acima da fossa antecubital em um plano longitudinal. A sala de exame &#233; mantida em uma temperatura de 21 graus e em sil&#234;ncio.</p>
    <p>O exame foi realizado com um aparelho de ecocardiografia (VIVID 3), da GE, equipado com <italic>software</italic> de ultrassom vascular bidimensional, doppler em cores e espectral, transdutor vascular linear de alta frequ&#234;ncia (7-12 mHz) e monitor interno de eletrocardiograma, que registra o tra&#231;ado de ECG em uma deriva&#231;&#227;o.</p>
    <p>Para a avalia&#231;&#227;o da vasodilata&#231;&#227;o endot&#233;lio dependente, no antebra&#231;o do paciente, foi colocado um esfigmoman&#244;metro, que &#233; insuflado com ar at&#233; 50 mmHg da press&#227;o sist&#243;lica encontrada. O manguito &#233; desinsuflado (cinco minutos) ap&#243;s, permitindo que ocorram isquemia e, por consequ&#234;ncia, vasodilata&#231;&#227;o por um mecanismo de autorregula&#231;&#227;o e hiperemia reativa.</p>
    <p>O fluxo da art&#233;ria braquial foi registrado pelo doppler em cores, continuamente de 30 s a 90 s ap&#243;s desinsuflar o manguito. Depois do registro por hiperemia reativa, o paciente fica em repouso por um per&#237;odo de dez minutos. Logo em seguida, inicia-se a avalia&#231;&#227;o pelo mecanismo de vasodilata&#231;&#227;o endot&#233;lio independente.</p>
    <p>A avalia&#231;&#227;o endot&#233;lio independente caracteriza-se pela administra&#231;&#227;o de nitroglicerina <italic>spray</italic> (0,4 mg) SL. Aguardamos, ent&#227;o, tr&#234;s minutos, que &#233; o tempo necess&#225;rio para que ocorra a vasodilata&#231;&#227;o. Ap&#243;s esse per&#237;odo, o fluxo da arteart&#233;ria braquial &#233; registrado pelo doppler em cores. O uso da nitroglicerina &#233; contraindicado a pacientes hipotensos e bradic&#225;rdicos.</p>
    <p>O di&#226;metro da art&#233;ria braquial foi medido por imagem longitudinal do vaso, calculando-se a dist&#226;ncia entre a &#237;ntima proximal e distal na di&#225;stole. Devido &#224; grande variabilidade na medida do di&#226;metro intimal, um &#250;nico ponto de reparo &#233; selecionado, e s&#227;o realizadas as medidas em cinco ciclos card&#237;acos. Essas medidas foram feitas acompanhando o ciclo card&#237;aco e usando o tra&#231;ado do eletrocardiograma durante a aquisi&#231;&#227;o das imagens. A onda R identifica o fim da di&#225;stole, e o pico da onda T, o fim da s&#237;stole.</p>
    <p>
      <graphic xlink:href="1678-4170-abc-93-04-0367-00009-e01.jpg"/></p>
    <p>A DILA foi calculada como o percentual de aumento do di&#226;metro p&#243;s oclus&#227;o da art&#233;ria braquial (DPOAB) em rela&#231;&#227;o aos seus valores basais (DBAB).</p>
    <p><bold>C&#225;lculo da DILA</bold>: (DPOAB - DBAB) / DBAB x 100%</p>
    <p>DBAB - di&#226;metro basal da art&#233;ria braquial</p>
    <p>Valores acima de 10% de varia&#231;&#227;o na dilata&#231;&#227;o da art&#233;ria braquial em rela&#231;&#227;o ao basal foram considerados normais.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>Para a verifica&#231;&#227;o de signific&#226;ncia estat&#237;stica nas vari&#225;veis cont&#237;nuas (num&#233;ricas) entre dois subgrupos, foi utilizado o teste t de Student para amostras independentes ou o teste de Mann-Whitney (n&#227;o param&#233;trico). Para a compara&#231;&#227;o de vari&#225;veis categ&#243;ricas (qualitativas), foi aplicado o teste de qui-quadrado (&#967;<sup>2</sup>) ou exato de Fisher.</p>
    <p>A an&#225;lise do comportamento das medidas da reatividade braquial ao longo do tempo (tr&#234;s medidas), separadas por subgrupos, foi realizada pela vari&#226;ncia (ANOVA) para medidas repetidas. O teste de compara&#231;&#245;es m&#250;ltiplas de Bonferroni (ajustado para medidas repetidas) foi aplicado para identificar quais os momentos que diferem entre si. Para verificar se o comportamento ao longo do tempo &#233; diferente entre os subgrupos, foi realizada a an&#225;lise de vari&#226;ncia para medidas repetidas com um fator.</p>
    <p>O coeficiente de correla&#231;&#227;o de Spearman foi usado para medir o grau de associa&#231;&#227;o entre o delta relativo com o perfil metab&#243;lico; e a an&#225;lise de regress&#227;o linear m&#250;ltipla foi realizada para verificar, simultaneamente, a influ&#234;ncia dos dados cl&#237;nicos e metab&#243;licos sobre o delta relativo da reatividade braquial pelo vasodilatador.</p>
    <p>Foram utilizados m&#233;todos n&#227;o param&#233;tricos, uma vez que algumas vari&#225;veis (Triglic&#233;rides (TG) e deltas relativos) n&#227;o apresentaram distribui&#231;&#227;o normal (distribui&#231;&#227;o Gaussiana) devido &#224; dispers&#227;o dos dados ou &#224; falta de simetria da distribui&#231;&#227;o.</p>
    <p>O crit&#233;rio de determina&#231;&#227;o de signific&#226;ncia adotado foi o n&#237;vel de 5%. A an&#225;lise estat&#237;stica foi processada pelo <italic>software</italic> SAS 6.04 (SAS Institute, Inc., Cary, North Carolina).</p>
    <p>
      <bold>&#201;tica</bold>
    </p>
    <p>A pesquisa foi aprovada pelo comit&#234; de &#233;tica em pesquisa da Faculdade de Medicina da Universidade Federal Fluminense. Para a coleta dos dados, os pacientes foram submetidos a um termo de consentimento livre e esclarecido.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Foram selecionados 27 pacientes HIV positivo, com idade m&#233;dia de 41,6 anos (+/- 8,5), provenientes do ambulat&#243;rio de SIDA da disciplina de doen&#231;as infecto parasit&#225;rias da Faculdade de Medicina da Universidade Federal Fluminense. Desse grupo, 15 pacientes (55,6%) fizeram uso de inibidores da protease.</p>
    <p>
      <graphic xlink:href="1678-4170-abc-93-04-0367-00009-e02.jpg"/></p>
    <p>Um grupo de 16 pacientes (37,2%), com idade m&#233;dia de 43,8 anos (+/- 4,3), formou o grupo controle.</p>
    <p>As vari&#225;veis demogr&#225;ficas e cl&#237;nico-laboratoriais s&#227;o ilustradas nas <xref ref-type="table" rid="t1">tabelas 1</xref> e <xref ref-type="table" rid="t2">2</xref>.</p>
    <table-wrap id="t1">
      <graphic xlink:href="1678-4170-abc-93-04-0367-00009-gt01.jpg"/></table-wrap>
    <table-wrap id="t2">
      <graphic xlink:href="1678-4170-abc-93-04-0367-00009-gt02.jpg"/></table-wrap>
    <p>N&#227;o houve diferen&#231;a significativa em rela&#231;&#227;o &#224; idade e ao sexo nos grupos HIV positivo e negativo (p = 0,27).</p>
    <p>Vari&#225;veis cont&#237;nuas como cintura abdominal (CA) e HDL-c foram significativamente menores no grupo HIV positivo com p = 0,010 e p = 0,050, respectivamente.</p>
    <p>Os pacientes HIV negativo com HAS (93,8% <italic>vs</italic> 14,8%; p &lt; 0,0001) apresentaram n&#237;veis press&#243;ricos mais elevados que os HIV positivo.</p>
    <p>O TG foi a vari&#225;vel metab&#243;lica predominante no subgrupo de pacientes HIV positivo e em uso de IP, com p = 0,004 e p = 0,009, em rela&#231;&#227;o aos HIV negativo e sem uso de IP.</p>
    <p>A <xref ref-type="table" rid="t03">tabela 3</xref> mostra os resultados do estudo de ultrassom da art&#233;ria braquial.</p>
    <p content-type="asset">
      <table-wrap id="t03">
        <graphic xlink:href="1678-4170-abc-93-04-0367-00009-gt03.jpg"/></table-wrap>
    </p>
    <p>Pela an&#225;lise de vari&#226;ncia para medidas repetidas, avaliou-se a reatividade braquial pela hiperemia reativa e vasodilatador em pacientes HIV positivo e negativo em tr&#234;s momentos (basal, 60 s e 90 s). Observou-se que existe aumento significativo na reatividade braquial pela hiperemia reativa no subgrupo HIV positivo (p = 0,033) e negativo (p = 0,014) at&#233; os 60 s. N&#227;o houve signific&#226;ncia estat&#237;stica aos 90 s para os pacientes HIV positivo.</p>
    <p>A an&#225;lise endot&#233;lio independente (uso de vasodilatador) apresentou aumento significativo na reatividade braquial em ambos os subgrupos positivo e negativo, com p = 0,0001 e p = 0,0001, respectivamente.</p>
    <p>Baseando-se ainda na an&#225;lise de vari&#226;ncia, comparou-se o subgrupo de pacientes em uso ou n&#227;o de IP aos 60 s e 90 s da reatividade braquial. Observou-se que existe aumento significativo por hiperemia reativa no subgrupo com uso de IP (p = 0,038) apenas aos 60 s, n&#227;o havendo signific&#226;ncia estat&#237;stica na medida aos 90 s.</p>
    <p>Com o uso de nitrato SL, observou-se aumento significativo da reatividade braquial nos subgrupos com e sem IP, com p = 0,016 e p = 0,0001, respectivamente.</p>
    <p>Apesar de observar-se aumento significativo nas medidas da reatividade braquial (hiperemia reativa e vasodilatador), principalmente do basal para 60 s, tanto no subgrupo HIV positivo quanto no em uso de IP, esse aumento &#233; diferenciado. Ou seja, o subgrupo HIV positivo ou com o uso de IP apresentaram aumento pelo vasodilatador significativamente menor que o subgrupo HIV negativo ou sem IP.</p>
    <p>Baseando-se na an&#225;lise do delta relativo (%) da reatividade braquial segundo o HIV e o IP, observou-se que aos 60 s tanto o grupo HIV positivo quanto o que usou IP apresentaram delta relativo pelo uso do vasodilatador significativamente menor que o grupo HIV negativo e o sem uso de IP, com p = 0,020 e p = 0,034, respectivamente.</p>
    <p>O delta relativo pela hiperemia reativa n&#227;o apresentou signific&#226;ncia estat&#237;stica em qualquer subgrupo.</p>
    <p>As <xref ref-type="table" rid="t04">tabelas 4</xref> e <xref ref-type="table" rid="t05">5</xref> mostram a an&#225;lise do delta relativo da reatividade braquial, segundo o HIV e o inibidor de protease, respectivamente.</p>
    <p content-type="asset">
      <table-wrap id="t04">
        <graphic xlink:href="1678-4170-abc-93-04-0367-00009-gt04.jpg"/></table-wrap>
    </p>
    <p content-type="asset">
      <table-wrap id="t05">
        <graphic xlink:href="1678-4170-abc-93-04-0367-00009-gt05.jpg"/></table-wrap>
    </p>
    <p>Vari&#225;veis como sexo, &#237;ndice de massa corporal (IMC), cintura abdominal (CA), glicemia, colesterol total (CT), HDL-c, LDL-c e TG n&#227;o mostraram signific&#226;ncia estat&#237;stica em rela&#231;&#227;o &#224; reatividade braquial.</p>
    <p>A an&#225;lise de regress&#227;o linear m&#250;ltipla observou que apenas o IP diminui o delta relativo nos pacientes HIV positivo, pelo vasodilatador aos 60 e 90 segundos, com p = 0,032 e p = 0,010, respectivamente.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Este estudo mostrou que pacientes infectados com HIV em uso de HAART, incluindo IP, h&#225; mais de dois anos apresentaram disfun&#231;&#227;o endotelial comparado ao grupo sem uso de IP e ao grupo controle n&#227;o infectado.</p>
    <p>A principal contribui&#231;&#227;o desses resultados em rela&#231;&#227;o aos estudos pr&#233;vios &#233; a demonstra&#231;&#227;o do comprometimento da resposta vasodilatadora endot&#233;lio independente nos pacientes HIV positivo em uso de IP.</p>
    <p>Estudos pr&#233;vios<sup>12</sup> t&#234;m avaliado a fun&#231;&#227;o endotelial em pacientes com HIV pela t&#233;cnica da DILA e correlacionado com a probabilidade de desenvolvimento de doen&#231;a arterial coronariana. A DILA &#233; uma t&#233;cnica n&#227;o invasiva, acurada e reprodut&#237;vel, por&#233;m &#233; dependente de caracter&#237;sticas operacionais ligadas &#224; frequ&#234;ncia do ultrassom e do treinamento t&#233;cnico.</p>
    <p>A disfun&#231;&#227;o endotelial por hiperemia reativa (endot&#233;lio dependente) e pelo uso de nitroglicerina (endot&#233;lio independente) foi analisada pelo estudo da art&#233;ria braquial em momentos diferentes de dilata&#231;&#227;o (60 s e 90 s). Segundo o protocolo validado<sup>12</sup>, o pico de libera&#231;&#227;o do oxido n&#237;trico (NO) e da dilata&#231;&#227;o da art&#233;ria ocorrem nesse per&#237;odo.</p>
    <p>Nosso estudo mostrou que, tanto no subgrupo de pacientes HIV positivo quanto daqueles em uso de IP, houve aumento da dilata&#231;&#227;o da art&#233;ria braquial por hiperemia reativa, n&#227;o havendo diferen&#231;a em rela&#231;&#227;o ao subgrupo HIV negativo e sem uso de IP.</p>
    <p>Nolan e cols.<sup>13</sup> n&#227;o encontraram diferen&#231;a na fun&#231;&#227;o endotelial quando compararam o fluxo da art&#233;ria braquial em 24 pacientes HIV positivo tratados com IP e 24 pacientes n&#227;o infectados do grupo controle<sup>13</sup>.</p>
    <p>Stein e cols.<sup>14</sup> mostraram diminui&#231;&#227;o da dilata&#231;&#227;o da art&#233;ria braquial em pacientes HIV positivo em uso de IP comparando com pacientes HIV positivo sem uso de IP<sup>14</sup>.</p>
    <p>A vasodilata&#231;&#227;o endot&#233;lio independente realizada pelo uso de NO ex&#243;geno relaciona-se &#224; fun&#231;&#227;o do m&#250;sculo liso. Em nosso estudo, apenas o IP foi significativo para influenciar o delta relativo pelo vasodilatador aos 60 e 90 segundos.</p>
    <p>Um estudo avaliou 800 pacientes assintom&#225;ticos sem HIV e com fatores de risco para doen&#231;a cardiovascular, pelo uso da nitroglicerina ex&#243;gena. Concluiu-se que a resposta reduzida ao uso de nitroglicerina se correlacionou &#224; idade aumentada, ao aumento do colesterol total, &#224; hist&#243;ria de <italic>diabetes mellitus</italic> e ao tabagismo<sup>15</sup>.</p>
    <p>Takase e cols.<sup>16</sup> analisaram a intera&#231;&#227;o entre HAS e DM na disfun&#231;&#227;o endot&#233;lio independente e separaram quatro grupos, sendo DM tipo 2, HAS, HAS/DM e controle. Os resultados mostraram que a vasodilata&#231;&#227;o induzida pela nitroglicerina foi reduzida no grupo de pacientes hipertensos e diab&#233;ticos comparado com o grupo controle (p &lt; 0,001), mostrando que a intera&#231;&#227;o entre DM e HAS pioram o endot&#233;lio vascular, bem como o m&#250;sculo liso respons&#225;vel pela vasodilata&#231;&#227;o endot&#233;lio independente<sup>16</sup>.</p>
    <p>O mecanismo de disfun&#231;&#227;o endotelial &#233; explicado tanto pela a&#231;&#227;o do v&#237;rus quanto pelo uso de HAART. Shankar e cols. demonstraram diminui&#231;&#227;o da dilata&#231;&#227;o da art&#233;ria braquial em crian&#231;as HIV positivas sem uso de antirretrovirais<sup>17</sup>. O v&#237;rus atua no endot&#233;lio por interm&#233;dio da glicoprote&#237;na 120 (Gp120), levando &#224; produ&#231;&#227;o de mol&#233;culas de ades&#227;o (ICAM-1), estados protromb&#243;ticos, TNF alfa e interleucina 6 (IL-6).</p>
    <p>Embora os IPs reduzam a &#243;xido n&#237;trico sintetase endotelial (eNOS), levando &#224; diminui&#231;&#227;o da produ&#231;&#227;o de &#243;xido n&#237;trico, as esp&#233;cies reativas de oxig&#234;nio (ROS) contribuem para a disfun&#231;&#227;o endotelial, levando &#224; inflama&#231;&#227;o, ao dano celular e &#224; apoptose das c&#233;lulas endoteliais. Os IPs induzem a forma&#231;&#227;o de ROS<sup>18</sup>. Mondal e cols.<sup>19</sup> demonstraram a presen&#231;a de ROS nas c&#233;lulas endoteliais da art&#233;ria aorta de pacientes em uso de Zidovudina e Efavirenz<sup>19</sup>.</p>
    <p>Os IPs tamb&#233;m levam &#224; disfun&#231;&#227;o do DNA mitocondrial, contribuindo para o aumento do estresse oxidativo. Cote e cols. mostraram o primeiro caso de disfun&#231;&#227;o mitocondrial em pacientes HIV positivo em uso de IP e com sintomas de hiperlactatemia<sup>20</sup>.</p>
    <p>Um dos principais mecanismos que explica a disfun&#231;&#227;o endotelial induzida pelo IP est&#225; relacionado &#224; ativa&#231;&#227;o de prote&#237;nas kinases (MAPKs) por esp&#233;cies reativas de oxig&#234;nio. Os IPs ativam diferentes tipos de MAPKs em diferentes c&#233;lulas<sup>21</sup>.</p>
    <p>As ROS tamb&#233;m est&#227;o presentes nas c&#233;lulas do m&#250;sculo liso, respons&#225;vel pela vasodilata&#231;&#227;o endot&#233;lio independente, levando &#224; disfun&#231;&#227;o endotelial pelo uso de NTG em pacientes que usam IP. Chai e cols.<sup>22,23</sup> demonstraram a presen&#231;a de anion super&#243;xido nas c&#233;lulas endoteliais do m&#250;sculo liso de pacientes tratados com IP<sup>22,23</sup>. Kim e cols.<sup>24</sup> mostraram que prote&#237;nas virais afetam a prolifera&#231;&#227;o das c&#233;lulas endoteliais do m&#250;sculo liso, representando o maior evento na forma&#231;&#227;o da les&#227;o vascular<sup>24</sup>.</p>
    <p>Estudos preliminares mostram que antioxidantes como a Ginsenoside e o Curcumin poder&#227;o reverter a disfun&#231;&#227;o endotelial causada pelos IPs, diminuindo as ROS<sup>25</sup>.</p>
    <p>A principal limita&#231;&#227;o de nosso estudo foi a presen&#231;a de hipertens&#227;o arterial no grupo de volunt&#225;rios, por&#233;m n&#227;o impediu a confirma&#231;&#227;o dos nossos achados em rela&#231;&#227;o &#224; disfun&#231;&#227;o vascular endot&#233;lio independente.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Os pacientes HIV positivo em uso de IP apresentam disfun&#231;&#227;o endot&#233;lio independente quando comparados a pacientes HIV positivo que n&#227;o fazem uso de IPs e a um grupo controle.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo foi parcialmente financiado pela CAPES.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Mestrado de Hamilton Nenrod Pereira Teixeira pela Universidade Federal Fluminense.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <label>
          <bold> Correspond&#234;ncia:</bold>
        </label>
        <p>Hamilton Nenrod Pereira Teixeira </p>
        <p> Rua dos Rouxin&#243;is, 7 / Q 8 / 404 </p>
        <p> Ed. Gramado Renascen&#231;a II </p>
        <p> 65.075-630, S&#227;o Luiz do Maranh&#227;o, MA - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="hnpteixeira@yahoo.com.br">hnpteixeira@yahoo.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 10/08/2008; revisado recebido em 09/11/2008; aceito em 09/12/2008.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Barbaro G. Pathogenesis    of HIV-associated heart disease. AIDS. 2003; 17: S12-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pathogenesis of HIV-associated heart disease</article-title>
          <source>AIDS</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>S12</fpage>
          <lpage>20</lpage>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barbaro</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Prendergast    BD. HIV and cardiovascular medicine. Heart. 2003; 89: 793-800.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>HIV and cardiovascular medicine</article-title>
          <source>Heart</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>793</fpage>
          <lpage>800</lpage>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Prendergast</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Barbaro G. Cardiovascular    manifestations of HIV infection. J R Soc Med. 2001; 94: 384-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular manifestations of HIV infection</article-title>
          <source>J R Soc Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>384</fpage>
          <lpage>90</lpage>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barbaro</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Murphy El, Collier    AC, Kalish LA. Highly active antiretroviral therapy decrease mortality and morbidity    in patients with advanced HIV disease. Ann Intern Med. 2001; 135: 17-26.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Highly active antiretroviral therapy decrease mortality and morbidity in patients with advanced HIV disease</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>17</fpage>
          <lpage>26</lpage>
          <volume>135</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Murphy El</surname>
            </name>
            <name>
              <surname>Collier</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Kalish</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Samaras K, Wand    H, Law M, Emery S, Cooper D, Carr A. Prevalence of Metabolic Syndrome in HIV-Infected    Patients Receiving Highly Active Antiretroviral Therapy Using International    Diabetes Foundation and Adult Treatment Panel III Criteria. Diabetes Care. 2007;    30: 113-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>113</fpage>
          <lpage>9</lpage>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Samaras</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wand</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Law</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Emery</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Carr</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Constant J,    Pellegrin Jl, Peuchant E. Plasma lipids in HIV-infected patients: a prospective    study in 95 patients. Eur J Clin Invest. 1994; 24: 416-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma lipids in HIV-infected patients: a prospective study in 95 patients</article-title>
          <source>Eur J Clin Invest</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>416</fpage>
          <lpage>20</lpage>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Constant</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pellegrin</surname>
              <given-names>Jl</given-names>
            </name>
            <name>
              <surname>Peuchant</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. The Data Collection    on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral    therapy and the risk of myocardial infarction. N Engl J Med. 2003; 349: 1993-2003.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Combination antiretroviral therapy and the risk of myocardial infarction</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1993</fpage>
          <lpage>2003</lpage>
          <volume>349</volume>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Henry K, Melroe    H, Huebsch J, Hermundson J, Levine C, Swensen L. Severe premature coronary artery    disease with protease inhibitors. Lancet. 1998; 351: 1328.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Severe premature coronary artery disease with protease inhibitors</article-title>
          <source>Lancet</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1328</fpage>
          <volume>351</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Henry</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Melroe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Huebsch</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hermundson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Swensen</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Chaparro J ,    Reeds D, Wen W, Xueping E, Klein S, Semenkovich C, et al. Alterations in thigh    subcutaneous adipose tissue gene expression in protease inhibitor-based highly    active antiretroviral therapy. Metabolism. 2005; 54: 561-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy</article-title>
          <source>Metabolism</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>561</fpage>
          <lpage>7</lpage>
          <volume>54</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chaparro</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Reeds</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Xueping</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Semenkovich</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Xu A, Yin S,    Wong L, Chan KW. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency    virus protease inhibitor ritonavir in mice. Endocrinology. 2004; 145: 487-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice</article-title>
          <source>Endocrinology</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>487</fpage>
          <lpage>94</lpage>
          <volume>145</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>KW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Blanco JJ,    Garcia IS, Cerezo JG, Rivera JM, Anaya PM, Raya PG, et al. Endothelial function    in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob    Chemother. 2006; 58: 133-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endothelial function in HIV-infected patients with low or mild cardiovascular risk</article-title>
          <source>J Antimicrob Chemother</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>133</fpage>
          <lpage>9</lpage>
          <volume>58</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Blanco</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>IS</given-names>
            </name>
            <name>
              <surname>Cerezo</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Rivera</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Anaya</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Raya</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Corretti MC,    Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines    for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation    of the brachial artery: a report of the International Brachial Artery Reactivity    Task Force. J Am Coll Cardiol. 2002; 39: 257-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>257</fpage>
          <lpage>65</lpage>
          <volume>39</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Corretti</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Celermajer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Charbonneau</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Creager</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Nolan D, Watts    GF, Herrmann SE, French MA, Jonh M, Mallal S. Endothelial function in HIV infected    patients receiving protease inhibitor therapy: does immune competence affect    cardiovascular risk? QJM. 2003; 96: 825-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endothelial function in HIV infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk?</article-title>
          <source>QJM</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>825</fpage>
          <lpage>32</lpage>
          <volume>96</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nolan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Watts</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Herrmann</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>French</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Jonh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mallal</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Stein JH, Klein    MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency    virus - 1 protease inhibitors in associated with atherogenic lipoprotein changes    and endothelial dysfunction. Circulation. 2001; 104: 257-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Use of human immunodeficiency virus - 1 protease inhibitors in associated with atherogenic lipoprotein changes and endothelial dysfunction</article-title>
          <source>Circulation</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>257</fpage>
          <lpage>62</lpage>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Bellehumeur</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>McBride</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Wiebe</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Otvos</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Ma L, Zhao    S, Li J, Zhou Q, Gao M. Interaction of hypertension and diabetes on impairment    of endothelial function. Chin Med J (Engl). 2001; 114 (6): 563-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Interaction of hypertension and diabetes on impairment of endothelial function</article-title>
          <source>Chin Med J (Engl)</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>563</fpage>
          <lpage>7</lpage>
          <issue>6</issue>
          <volume>114</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Takase B, Uehata    A, Akima T, Nagai T, Nishioca T, Hamabe A, et al. Endothelium-dependent flow    mediated vasodilation in coronary and brachial arteries in suspected coronary    artery disease. Am J Cardiol. 1998; 82: 1535-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endothelium-dependent flow mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1535</fpage>
          <lpage>9</lpage>
          <volume>82</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Takase</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Uehata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Akima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nagai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nishioca</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hamabe</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Shankar SS,    Dube MP. Clinical aspects of endothelial dysfunction associated with human immunodeficiency    virus infection and antiretroviral agents. Cardiovasc Toxicol. 2004; 4: 261-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents</article-title>
          <source>Cardiovasc Toxicol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>261</fpage>
          <lpage>9</lpage>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shankar</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Dube</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Rush JW, Denniss    SG, Graham DA. Vascular nitric oxide and oxidative stress: determinants of endothelial    adaptations to cardiovascular disease and to physical activity. Can J Appl Physiol.    2005; 30 : 442-74.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity</article-title>
          <source>Can J Appl Physiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>442</fpage>
          <lpage>74</lpage>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rush</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Denniss</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Mondal D, Pradhan    L, Ali M, Agrawal KC. HAART drugs induce oxidative stress in human endothelial    cells and increase endothelial recruitment of mononuclear cells. Cardiovasc    Toxicol. 2004; 4: 287-302.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells</article-title>
          <source>Cardiovasc Toxicol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>287</fpage>
          <lpage>302</lpage>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mondal</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pradhan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Agrawal</surname>
              <given-names>KC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. C&#244;t&#233;    H, Brumme ZL, Craib K, Alexander CS, Wynhoven B, Wong H, et al. Changes in mitochondrial    DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med.    2002; 346: 811-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>811</fpage>
          <lpage>20</lpage>
          <volume>346</volume>
          <person-group person-group-type="author">
            <name>
              <surname>C&#244;t&#233;</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Brumme</surname>
              <given-names>ZL</given-names>
            </name>
            <name>
              <surname>Craib</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Wynhoven</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Wang X, Chai    H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial    dysfunction. J Acquir Immune Defic Syndr. 2007; 44: 493-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction</article-title>
          <source>J Acquir Immune Defic Syndr</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>493</fpage>
          <lpage>9</lpage>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Chai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Chai H, Zhou    W, Lin P, Lumsden A, Yao Q, Chen C. Ginsenosides block HIV protease inhibitor    ritonavir-induced vascular dysfunction of porcine coronary arteries. Am J Physiol    Heart Circ Physiol. 2005; 288: H2965 - H2971.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine coronary arteries</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>H2965</fpage>
          <lpage>H2971</lpage>
          <volume>288</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lumsden</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Chai H, Yan    S, Peter L, Alan BL, Yao Q, Chen C. Curcumin blocks HIV protease inhibitor ritonavir-induced    vascular dysfunction in porcine coronary arteries. J Am Coll Surg. 2005; 200:    820-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Curcumin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine coronary arteries</article-title>
          <source>J Am Coll Surg</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>820</fpage>
          <lpage>30</lpage>
          <volume>200</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Peter</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Alan</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Kim J, Ruff    M, Karwatowska-Prokopczuk E, Hunt L, Ji H, Pert CB, et al. HIV envelope protein    gp120 induces neuropeptide y receptor-mediated proliferation of vascular smooth    muscle cells: relevance to AIDS cardiovascular pathogenesis. Regul Pept. 1998;    75-76: 201-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>HIV envelope protein gp120 induces neuropeptide y receptor-mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis</article-title>
          <source>Regul Pept.</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>75</fpage>
          <lpage>76</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ruff</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Karwatowska-Prokopczuk</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hunt</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pert</surname>
              <given-names>CB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Center for    Disease Control and Prevention (CDC). Pneumocystis pneumonia, Los Angeles. 1981.    MMWR Morb Mortal Wkly Rep. 1996; 45 (34): 729-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pneumocystis pneumonia, Los Angeles. 1981</article-title>
          <source>MMWR Morb Mortal Wkly Rep</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>729</fpage>
          <lpage>33</lpage>
          <issue>34</issue>
          <volume>45</volume>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Study of vascular reactivity in HIV patients whether or not receiving protease inhibitor</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: A great number of HIV-infected patients using antiretroviral drugs develop endothelial dysfunction and atherothrombosis, which lead to a high medical and social burden. Thus, it is important to identify pathophysiological mechanisms involved with the endothelial function in these patients, so that early intervention can be made to avoid disease progression. OBJECTIVE: To evaluate endothelial function using endothelium-dependent and independent vasodilation in HIV-positive patients and in a control group. METHODS: A total of 27 HIV-positive patients and 16 controls were evaluated. Endothelium-dependent (reactive hyperemia) and independent (SL nitroglycerine) vasodilation of the brachial artery was used to evaluate the endothelial function. RESULTS: HIV-positive patients receiving protease inhibitors (PI) showed significantly lower endothelium-independent vasodilation than the HIV-negative (p=0.020) and HIV-positive without PI (p=0.034) subgroups. The change in brachial artery diameter during active hyperemia was not statistically significant in any subgroup. Multiple linear regression analysis showed that only PI was associated with the relative delta of brachial reactivity to vasodilator in HIV-positive patients at 60s and 90s. CONCLUSION: HIV-positive patients receiving PI presented endothelium-independent dysfunction when compared to HIV-positive patients not receiving PI and to the control group.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Endothelium, vascular</kwd>
        <kwd>HIV</kwd>
        <kwd>protease inhibitors</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Study of vascular reactivity in hiv patients whether or not receiving protease inhibitor </bold>
          </label>
          <p>
            <bold>Hamilton Nenrod Pereira Teixeira; Evandro Tinoco Mesquita; M&#225;rio Luiz Ribeiro; Anna Ricordi Bazin; Cl&#225;udio Tinoco Mesquita; Manuel Pereira Teixeira; Rafael da Cunha Pellegrini; Antonio Claudio Lucas da N&#243;brega</bold>
          </p>
        </fn>
      </p>
      <p>Universidade Federal Fluminense (UFF), Niter&#243;i, RJ - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND: </bold> A great number of HIV-infected patients using antiretroviral drugs develop endothelial dysfunction and atherothrombosis, which lead to a high medical and social burden. Thus, it is important to identify pathophysiological mechanisms involved with the endothelial function in these patients, so that early intervention can be made to avoid disease progression.</p>
      <p><bold>OBJECTIVE: </bold> To evaluate endothelial function using endothelium-dependent and independent vasodilation in HIV-positive patients and in a control group.</p>
      <p><bold>METHODS: </bold> A total of 27 HIV-positive patients and 16 controls were evaluated. Endothelium-dependent (reactive hyperemia) and independent (SL nitroglycerine) vasodilation of the brachial artery was used to evaluate the endothelial function.</p>
      <p><bold>RESULTS: </bold> HIV-positive patients receiving protease inhibitors (PI) showed significantly lower endothelium-independent vasodilation than the HIV-negative (p=0.020) and HIV-positive without PI (p=0.034) subgroups.</p>
      <p> The change in brachial artery diameter during active hyperemia was not statistically significant in any subgroup. Multiple linear regression analysis showed that only PI was associated with the relative delta of brachial reactivity to vasodilator in HIV-positive patients at 60s and 90s.</p>
      <p><bold>CONCLUSION:</bold> HIV-positive patients receiving PI presented endothelium-independent dysfunction when compared to HIV-positive patients not receiving PI and to the control group.</p>
      <p><bold>Key Words:</bold> Endothelial dysfunction; vascular Doppler; HIV.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>By the end of the 1980's, Human Immunodeficiency Virus (HIV)-infected patients had short survival<sup>1</sup>. In contrast, in the early 21st century, there was an increase in the life expectancy of these patients thanks to the impact of the treatment with new antiretroviral drugs - the Highly Active Antiretroviral Therapy (HAART)<sup>2,3</sup>. HAART improves the prognosis of HIV-infected patients by reducing the incidence of opportunistic infections, hospitalizations and mortality<sup>4</sup>.</p>
      <p>Several factors contribute to the increase in cardiovascular disease risk in HIV patients, such as chronic inflammation due to the viral infection, PI action, and interaction with traditional risk factors<sup>5</sup>. Therefore, the predisposition to atherosclerosis results from cumulative exposure to the virus and from metabolic changes secondary to the use of PI, thus determining an unfavorable metabolic profile characterized by hypertriglyceridemia, low HLD-c and insulin resistance observed in 25 to 60% of the patients<sup>6</sup>.</p>
      <p>PIs are currently considered independent cardiovascular risk factors and are associated with an increase by 26% in the rate of acute myocardial infarction (AMI) per year of exposure in the patients who had started treatment for at least 4 to 6 years<sup>7</sup>. In 1998, the first two cases of premature coronary artery disease were demonstrated in two young HIV-positive patients receiving PI<sup>8</sup>.</p>
      <p>Several studies have demonstrated that endothelial dysfunction occurs in the early stages of insulin resistance found in patients receiving HAART. Hypoadiponectinemia is one of the factors responsible for lipodystrophy and metabolic disorder in HIV patients receiving PI<sup>9,10</sup>. Endothelial dysfunction is a premature event in the development of atherosclerotic lesions and may be easily measured using non-invasive ultrasound study of the brachial artery flow<sup>11</sup>. The mechanisms that lead to endothelial dysfunction in HIV-positive patients receiving PI remain not fully understood.</p>
      <p>The objective of this study was to evaluate the endothelium-dependent and independent function by means of the non-invasive method of flow-mediated vasodilation of the brachial artery (DILA), using ultrasound study in HIV-positive patients with and without HAART. DILA was compared in three groups: HIV-infected patients not receiving PI, HIV-infected patients receiving PI, and HIV-negative controls.</p>
      <p>
        <bold>Methodology</bold>
      </p>
      <p>A total of 43 patients of both genders aged between 20 and 55 years who had undergone clinical and laboratory assessment and the 1-day protocol for non-invasive ultrasound study of the endothelial function were included in the study.</p>
      <p>Group I included 15 HIV-positive patients in chronic use (&gt; 2 years) of PI, and group II included 12 HIV-positive PI-na&#239;ve patients. A control group of 16 HIV-negative volunteers of both genders was also evaluated.</p>
      <p>Exclusion criteria were the presence of coronary artery disease; cerebrovascular disease; peripheral vascular disease; use of contraceptives;ventricular dysfunction (left ventricular ejection fraction &lt; 45% using Simpson's rule); plasma creatinine &gt; 1.5 mg%; neoplastic diseases; and thyroid diseases.</p>
      <p>Data from the patient's clinical history included age, gender, weight (kg), body mass index (BMI), smoking and stage of HIV infection according to CD4 (T helper lymphocytes).</p>
      <p>
        <bold>Endothelial function study - protocol</bold>
      </p>
      <p>The technique used was that described by Celermajer et al and recommended by the International Brachial Artery Reactivity Task Force<sup>12</sup>.</p>
      <p>The subjects fasted for at least eight hours, and were required not to exercise in the day before the test or ingest substances that might affect arterial vasodilation, such as caffeine, vitamin C and cigarette. Women should be assessed out of their menstrual period.</p>
      <p>The subjects were placed in the supine position with the arm comfortably leaning on a proper support. The brachial artery was imaged above the antecubital fossa in the longitudinal plane. The room was kept quiet, at a temperature of 21 degrees Celsius.</p>
      <p>The tests were performed in a GE ultrasound scanner (VIVID 3) equipped with a vascular software for two-dimensional imaging, color and spectral Doppler, high-frequency (7-12 MHZ) linear vascular transducer, and internal electrocardiogram monitor for the record of a one-lead ECG tracing.</p>
      <p>For the assessment of endothelium-dependent vasodilation, a sphygmomanometer was placed around the patient's arm and the cuff was inflated with air up to 50 mmHg above the systolic blood pressure found. The cuff was deflated 5 minutes later, thus permitting that ischemia be followed by vasodilation via an autoregulatory mechanism and reactive hyperemia.</p>
      <p>The brachial artery flow was continuously recorded by the color-Doppler from 30s to 90s after cuff deflation. After the reactive hyperemia phase recording, the patient rested for 10 minutes. Then, assessment of endothelium-independent vasodilation was started.</p>
      <p>
        <graphic xlink:href="1678-4170-abc-93-04-0367-00009-e01-en.jpg"/></p>
      <p>
        <graphic xlink:href="1678-4170-abc-93-04-0367-00009-e02-en.jpg"/></p>
      <p>This was characterized by the administration of SL nitroglycerine spray (0.4 mg), with a 3-minute-long wait, which is the time necessary for vasodilation to occur. After this period of time, the brachial artery flow was recorded by color-Doppler. The use of nitroglycerin is contraindicated in individuals with hypotension and bradycardia.</p>
      <p>The diameter of the brachial artery was measured from its longitudinal image, by calculating the distance between the near and far intima during diastole. Because of the wide variability in the measurement of the intima diameter, a single reference point was selected and the measurements were taken in five cardiac cycles. The measurements were taken at the same time in the cardiac cycle, using electrocardiographic gating during image acquisition. The R wave was used to identify end diastole, and the peak of the T wave, end systole.</p>
      <p>DILA was calculated as the post-occlusion percentage increase in the diameter of the brachial artery (PODBA) in relation to baseline values.</p>
      <p><bold>DILA CALCULATION</bold>: (PODBA - BDBA) / BDBA X 100%</p>
      <p>BDBA - baseline diameter of the brachial artery</p>
      <p>Values higher than 10% of variation in brachial artery dilation in relation to baseline were considered normal.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Student's t test for independent samples or the Mann-Whitney (non-parametric) test were used to analyze the statistical significance of the differences in continuous (numeric) variables between two subgroups. The chi square test (&#967;<sup>2</sup>) or the Fisher's exact test were used for the comparison of categorical (qualitative) variables.</p>
      <p>The repeated measures analysis of variance (ANOVA) was used to study the behavior of brachial artery reactivity measurements throughout time (three measurements), separated by subgroups. Bonferroni's multiple comparison test (adjusted for repeated measures) was used to identify which moments were different between themselves. One-factor repeated measures ANOVA was carried out to verify whether the behavior throughout time was different between the subgroups</p>
      <p>The Spearman correlation coefficient was used to measure the degree of association between the relative delta and the metabolic profile; multiple linear regression analysis was used to simultaneously verify the influence of clinical and metabolic data on the relative delta of brachial reactivity to vasodilator.</p>
      <p>Non-parametric methods were used since some variables (TG and relative deltas) were not normally distributed (Gaussian distribution) due to scattered data and/or skewness.</p>
      <p>The significance level was set at 5%. The statistical analysis was carried out using the SAS 6.04 software (SAS Institute, Inc., Cary, North Carolina).</p>
      <p>
        <bold>Ethics</bold>
      </p>
      <p>This study was approved by the research ethics committee of the <italic>Universidade Federal Fluminense</italic> School of Medicine. For data collection, all patients gave their informed consent.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>Twenty seven HIV-positive patients with mean age of 41.6 years (&#177; 8.5) from the AIDS outpatient clinic of the discipline of Infectious and Parasitic Diseases of the <italic>Universidade Federal Fluminense</italic> School of Medicine were selected. Of these, 15 patients (55.6%) were receiving protease inhibitors.</p>
      <p>A group of 16 patients (37.2%) with mean age of 43.8 (&#177; 4.3) comprised the control group.</p>
      <p>Demographic, clinical and laboratory variables are shown in <xref ref-type="table" rid="t1-body2">Tables 1</xref> and <xref ref-type="table" rid="t2-body2">2</xref>.</p>
      <table-wrap id="t1-body2">
        <graphic xlink:href="1678-4170-abc-93-04-0367-00009-gt01-en.jpg"/></table-wrap>
      <table-wrap id="t2-body2">
        <graphic xlink:href="1678-4170-abc-93-04-0367-00009-gt02-en.jpg"/></table-wrap>
      <p>No significant difference was found in relation to age and gender between the HIV-positive and negative groups (p = 0.27).</p>
      <p>Continuous variables such as waist circumference (WC) and HDL-c were significantly lower in the HIV-positive group, with p = 0.010 and p = 0.050, respectively.</p>
      <p>HIV-negative patients with hypertension (93.8% versus 14.8%; p &lt; 0.0001) had higher blood pressure levels than HIV-positive patients.</p>
      <p>TG was the predominant metabolic variable in the subgroup of HIV-positive patients receiving PI with p = 0.004 and p = 0.009 in relation to HIV-negative patients not receiving PI.</p>
      <p>Results of brachial artery ultrasound studies are shown in <xref ref-type="table" rid="en_09t03-body2">Table 3</xref>.</p>
      <p content-type="asset">
        <table-wrap id="en_09t03-body2">
          <graphic xlink:href="1678-4170-abc-93-04-0367-00009-gt03-en.jpg"/></table-wrap>
      </p>
      <p>Using the repeated measures ANOVA, brachial reactivity to reactive hyperemia and vasodilators was evaluated in HIV-positive and HIV-negative patients at three timepoints (baseline, 60s, and 90s). A significant increase in brachial reactivity to reactive hyperemia was observed in the HIV-positive (p = 0.033) and HIV-negative (p =0.014) subgroups up to 60 s. No statistical significance was found for HIV-positive patients at 90s.</p>
      <p>The endothelium-independent analysis (use of vasodilator) showed a significant increase in brachial reactivity in both the positive and negative subgroups, with p = 0.0001 and p = 0.0001, respectively.</p>
      <p>Also using ANOVA, the subgroups of patients receiving and not receiving PI were compared at 60s and 90s of brachial reactivity, showing a significant increase to reactive hyperemia in the subgroup with PI (p = 0.038) only at 60s, with no statistical significance for this measurement at 90s.</p>
      <p>Using SL nitrate, a significant increase in brachial reactivity was observed in the subgroups with and without PI, with p = 0.016 and p = 0.0001, respectively.</p>
      <p>Although a significant increase in brachial reactivity measurements (reactive hyperemia and vasodilator) was observed, especially from baseline to 60s, both in the HIV-positive and in the PI subgroups, this increase was differentiated, that is, HIV-positive or with PI subgroups showed significantly lower increase to vasodilator than the HIV-negative or without PI subgroups.</p>
      <p>Based on the analysis of the relative delta (%) of brachial reactivity according to the HIV status and use of PI, we observed that, at 60s, both the HIV-positive and with PI groups had significantly lower relative delta to the use of vasodilator than the HIV-negative and without PI groups, with p = 0.020 and p = 0.034, respectively.</p>
      <p>No statistical significance was found for the relative delta to reactive hyperemia in any of the subgroups.</p>
      <p>The analysis of the relative delta of brachial reactivity according to the HIV status and use of protease inhibitor (PI) is shown in <xref ref-type="table" rid="en_09t04-body2">Tables 4</xref> and <xref ref-type="table" rid="en_09t05-body2">5</xref>, respectively.</p>
      <p content-type="asset">
        <table-wrap id="en_09t04-body2">
          <graphic xlink:href="1678-4170-abc-93-04-0367-00009-gt04-en.jpg"/></table-wrap>
      </p>
      <p content-type="asset">
        <table-wrap id="en_09t05-body2">
          <graphic xlink:href="1678-4170-abc-93-04-0367-00009-gt05-en.jpg"/></table-wrap>
      </p>
      <p>Variables such as gender; body mass index (BMI); waist circumference (WC); blood glucose; total cholesterol (TC); HDL-c; LDL-c; and TG showed no statistical difference in relation to brachial reactivity.</p>
      <p>Multiple linear regression analysis showed that only PI decreased the relative delta in HIV-positive patients in response to vasodilator at 60s and 90s, with p = 0.032 and p = 0.010, respectively.</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>This study showed that HIV-positive patients receiving HAART, including PI, for more than two years, presented endothelial dysfunction in comparison to the group without PI and to the non-infected control group.</p>
      <p>The main contribution of these findings in relation to previous studies is the demonstration of the impaired endothelium-independent vasodilation response in HIV-positive patients receiving PI.</p>
      <p>Previous studies<sup>12</sup> have assessed endothelial function in HIV patients by means of the DILA technique, correlating it with the likelihood of development of coronary artery disease. DILA is a noninvasive, accurate and reproducible technique, albeit dependent on operational characteristics related to the ultrasound frequency and technical training.</p>
      <p>Endothelial dysfunction to reactive hyperemia (endothelium-dependent) and to the use of nitroglycerine (endothelium-independent) was analyzed by means of the study of the brachial artery at different timepoints of dilation (60 and 90 seconds). According to a validated protocol<sup>12</sup>, the nitric oxide (NO) peak release and artery dilation occur in this period.</p>
      <p>Our study showed that both in the subgroup of HIV-positive patients and in that of patients using PI, there was increased brachial artery dilation to reactive hyperemia, with no difference in relation to the HIV-negative subgroup and the subgroup without PI.</p>
      <p>Nolan et al<sup>13</sup> did not find any difference in endothelial function when they compared the brachial artery flow in 24 HIV-positive patients treated with PI and 24 HIV-negative patients of the control group<sup>13</sup>.</p>
      <p>Stein et al<sup>14</sup> showed decreased brachial artery dilation in HIV-positive patients receiving PI in comparison to HIV-positive patients not receiving PI<sup>14</sup>.</p>
      <p>Endothelium-independent vasodilation using exogenous NO is related to the smooth muscle function. In our study, only PI significantly influenced the relative delta to vasodilator at 60 and 90 seconds.</p>
      <p>A study evaluated 800 asymptomatic HIV-negative patients with risk factors for cardiovascular disease by using exogenous nitroglycerin; it concluded that the reduced response to nitroglycerin was correlated with advanced age, increased total cholesterol, history of diabetes mellitus and smoking<sup>15</sup>.</p>
      <p>Takase et al<sup>16</sup> analyzed the interaction between hypertension and DM in endothelium-independent dysfunction in four groups divided into type-2 DM, hypertension, hypertension / DM, and control. The results showed that nitroglycerine-induced vasodilation was decreased in the group of patients with hypertension and diabetes in comparison to the control group (p &lt; 0.001), thus showing that the interaction between DM and hypertension caused deterioration of both the vascular endothelium and the smooth muscle responsible for endothelium-independent vasodilation<sup>16</sup>.</p>
      <p>The mechanism of endothelial dysfunction is explained by both the viral action and the use of HAART. Shankar et al demonstrated a reduction in brachial artery dilation in HIV-positive children not receiving antiretroviral drugs<sup>17</sup>. The virus acts on the endothelium by means of glycoprotein 120 (Gp120), leading to the production of adhesion molecules (ICAM-1), prothrombotic states, TNF alpha and interleukin 6 (IL-6).</p>
      <p>Although PIs reduce endothelial nitric oxide synthase (eNOS), which leads to a decreased production of nitric oxide, reactive oxygen species (ROS) contribute to endothelial dysfunction, thus resulting in inflammation, cell damage, and endothelial cell apoptosis. PIs induce ROS formation<sup>18</sup>. Mondal et al<sup>19</sup> demonstrated the presence of ROS in aortic endothelial cells of patients receiving zidovudine and efavirenz<sup>19</sup>.</p>
      <p>PIs also lead to mitochondrial DNA dysfunction, thus contributing to increased oxidative stress. Cote et al showed the first case of mitochondrial dysfunction in HIV-positive patients receiving PI and presenting symptoms of hyperlactatemia<sup>20</sup>.</p>
      <p>One of the main mechanisms explaining PI-induced endothelial dysfunction is related to protein kinase activation (MAPKs) by reactive oxygen species. PIs activate different types of MAPKs in different cells<sup>21</sup>.</p>
      <p>ROS are also present in cells of the smooth muscle, which is responsible for endothelium-independent vasodilation, thus leading to endothelial dysfunction with the use of NTG in patients receiving PI. Chai et al<sup>22,23</sup> demonstrated the presence of the superoxide anion in endothelial smooth muscle cells of patients treated with PI<sup>22,23</sup>. Kim et al<sup>24</sup> demonstrated that viral proteins affect the proliferation of endothelial smooth muscle cells, which represents the greatest event in the formation of vascular lesion<sup>24</sup>.</p>
      <p>Preliminary studies showed that antioxidants such as ginsenoside and curcumin may reverse the endothelial dysfunction caused by PIs, thus decreasing ROS<sup>25</sup>.</p>
      <p>The major limitation of our study was the presence of hypertension in the group of volunteers, which, however, did not preclude the confirmation of our findings in relation to the endothelium-independent vascular dysfunction.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>HIV-positive patients receiving PI present endothelium-independent dysfunction when compared to HIV-positive patients not receiving PI, as well as to the control group individuals.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was partially funded by CAPES.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of master submitted by Hamilton Nenrod Pereira Teixeira, from Universidade Federal Fluminense.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Estudio de la reactividad vascular en portadores de VIH con y sin uso de inhibidor de proteasa</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: Considerando el alto n&#250;mero de pacientes infectados por VIH en uso de antirretrovirales, evolucionando con la alteraci&#243;n de la funci&#243;n endotelial y aterotrombosis, llevando al alto coste m&#233;dico social, es importante identificar mecanismos fisiopatol&#243;gicos implicados en la funci&#243;n endotelial en portadores de VIH, para que, precozmente, podamos intervenir y evitar la progresi&#243;n de la enfermedad. OBJETIVO: Evaluar la funci&#243;n endotelial por la vasodilataci&#243;n endotelio dependiente e independiente en pacientes VIH positivo y en grupo control. M&#201;TODOS: El estudio evalu&#243; a 27 pacientes VIH positivo y a 16 del grupo control. La evaluaci&#243;n de la funci&#243;n endotelial se llev&#243; a cabo mediante la vasodilataci&#243;n de la arteria braquial endotelio dependiente (hiperemia reactiva) e independiente (nitroglicerina SL). RESULTADOS: Pacientes VIH positivo en uso de inhibidor de proteasa (IP) presentaron vasodilataci&#243;n endotelio independiente significativamente menor que los subgrupos VIH negativo (p = 0,020) y VIH positivo sin uso de IP (p = 0,034). La variaci&#243;n del di&#225;metro de la arteria braquial durante hiperemia reactiva no present&#243; significancia estad&#237;stica en cualquier subgrupo. El an&#225;lisis de regresi&#243;n lineal m&#250;ltiple evidenci&#243; que apenas el IP estaba asociado al delta relativo de la reactividad braquial por el vasodilatador, en los pacientes VIH positivo, a los 60 y 90 segundos. CONCLUSI&#211;N: Los pacientes VIH positivo en uso de IP presentan disfunci&#243;n endotelio independiente cuando comparados a pacientes VIH positivo que no est&#225;n en tratamiento con IP y a un grupo control.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Endotelio vascular</kwd>
        <kwd>VIH</kwd>
        <kwd>inhibidores de proteasas</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Estudio de la reactividad vascular en portadores de VIH con y sin uso de inhibidor de proteasa</bold>
          </label>
          <p>
            <bold>Hamilton Nenrod Pereira Teixeira; Evandro Tinoco Mesquita; M&#225;rio Luiz Ribeiro; Anna Ricordi Bazin; Cl&#225;udio Tinoco Mesquita; Manuel Pereira Teixeira; Rafael da Cunha Pellegrini; Antonio Claudio Lucas da N&#243;brega</bold>
          </p>
        </fn>
      </p>
      <p>UniversEdad Federal Fluminense (UFF), Niter&#243;i, RJ - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> Considerando el alto n&#250;mero de pacientes infectados por VIH en uso de antirretrovirales, evolucionando con la alteraci&#243;n de la funci&#243;n endotelial y aterotrombosis, llevando al alto coste m&#233;dico social, es importante identificar mecanismos fisiopatol&#243;gicos implicados en la funci&#243;n endotelial en portadores de VIH, para que, precozmente, podamos intervenir y evitar la progresi&#243;n de la enfermedad.</p>
      <p><bold>OBJETIVO: </bold> Evaluar la funci&#243;n endotelial por la vasodilataci&#243;n endotelio dependiente e independiente en pacientes VIH positivo y en grupo control.</p>
      <p><bold>M&#201;TODOS:</bold> El estudio evalu&#243; a 27 pacientes VIH positivo y a 16 del grupo control. La evaluaci&#243;n de la funci&#243;n endotelial se llev&#243; a cabo mediante la vasodilataci&#243;n de la arteria braquial endotelio dependiente (hiperemia reactiva) e independiente (nitroglicerina SL).</p>
      <p><bold>RESULTADOS:</bold> Pacientes VIH positivo en uso de inhibidor de proteasa (IP) presentaron vasodilataci&#243;n endotelio independiente significativamente menor que los subgrupos VIH negativo (p = 0,020) y VIH positivo sin uso de IP (p = 0,034). La variaci&#243;n del di&#225;metro de la arteria braquial durante hiperemia reactiva no present&#243; significancia estad&#237;stica en cualquier subgrupo. El an&#225;lisis de regresi&#243;n lineal m&#250;ltiple evidenci&#243; que apenas el IP estaba asociado al delta relativo de la reactividad braquial por el vasodilatador, en los pacientes VIH positivo, a los 60 y 90 segundos.</p>
      <p><bold>CONCLUSI&#211;N: </bold> Los pacientes VIH positivo en uso de IP presentan disfunci&#243;n endotelio independiente cuando comparados a pacientes VIH positivo que no est&#225;n en tratamiento con IP y a un grupo control.</p>
      <p><bold>Palabras clave: </bold> Endotelio vascular / fisiopatolog&#237;a, VIH, inhibidores de proteasas.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Al final de la d&#233;cada de 80, los pacientes infectados por el Virus de la Inmunodeficiencia humana (VIH) ten&#237;an una peque&#241;a sobrevida<sup>1</sup>. Por otra parte, a principios del siglo XXI, hay una mejora de la expectativa de vida de esos pacientes, debido al impacto de la terapia con nuevos f&#225;rmacos antirretrovirales (de sus siglas en ingl&#233;s, <italic>Highly Active Anti-retroviral Therapy</italic> - HAART)<sup>2,3</sup>. La HAART mejora el pron&#243;stico de los pacientes infectados por el virus VIH, disminuyendo la incidencia de infecciones oportunistas, hospitalizaci&#243;n y mortalidad<sup>4</sup>.</p>
      <p>Diversos factores contribuyen para el aumento del riesgo de enfermedad cardiovascular en los portadores de VIH, tales como la inflamaci&#243;n cr&#243;nica debido a la infecci&#243;n por el virus, a la acci&#243;n de los IPs y la interacci&#243;n con factores de riesgo tradicionales<sup>5</sup>. Por tanto, la predisposici&#243;n a la aterosclerosis resulta de la exposici&#243;n cumulativa al virus y de alteraciones metab&#243;licas secundarias al uso de IP, determinando un perfil metab&#243;lico desfavorable, caracterizado por hipertrigliceridemia, HDL-c bajo y resistencia insul&#237;nica que ocurre desde el 25% al 60% de los pacientes<sup>6</sup></p>
      <p>Actualmente se consideran los IPs como un factor de riesgo cardiovascular independiente y est&#225;n asociados al aumento del 26% de la tasa de infarto agudo de miocardio (IAM) por a&#241;o de exposici&#243;n, en pacientes que iniciaron el tratamiento desde hace, como m&#237;nimo, cuatro a&#241;os<sup>7</sup>. En el 1998, se evidenciaron los primeros casos de enfermedad coronaria prematura en dos j&#243;venes VIH positivo en uso de IP<sup>8</sup>.</p>
      <p>Diversos estudios revelaron que la disfunci&#243;n endotelial ocurre en los estadios iniciales de la resistencia insul&#237;nica presente en pacientes en uso de HAART. La hipoadiponectinemia es uno de los responsables por la lipodistrofia y por el disturbio metab&#243;lico en los pacientes VIH positivo en uso de IP<sup>9,10</sup>. La disfunci&#243;n endotelial es un evento prematuro en el desencadenamiento de las lesiones ateroscler&#243;ticas y puede ser f&#225;cilmente medida de manera no invasiva mediante la evaluaci&#243;n de ultrasonido del flujo de la arteria braquial<sup>11</sup>. Los mecanismos que conllevan la disfunci&#243;n endotelial en los pacientes VIH positivo en uso de IP no est&#225;n todav&#237;a explicados por completo.</p>
      <p>El objetivo de este estudio es que se eval&#250;e la funci&#243;n del endotelio dependiente e independiente, por m&#233;todo no invasivo de la dilataci&#243;n flujo mediada de la arteria braquial (DILA) por medio del ultrasonido en pacientes VIH positivo con y sin uso de HAART. Comparamos la DILA en tres grupos: VIH infectado sin uso de IP, VIH infectado en uso de IP y controles sin VIH.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>El estudio evalu&#243; a 43 pacientes con edades entre 20 y 55 a&#241;os, de ambos los sexos, que fueron sometidos a la evaluaci&#243;n cl&#237;nico-laboratorial y al protocolo de un d&#237;a para evaluaci&#243;n no invasiva de la funci&#243;n endotelial mediante la ultrasonograf&#237;a.</p>
      <p>El grupo l involucr&#243; a 15 pacientes VIH positivo en uso cr&#243;nico de IP (desde hace dos a&#241;os) y el grupo II con 12 pacientes VIH positivo sin uso previo de IP. Un grupo control de 16 voluntarios de ambos sexos y se evalu&#243; asimismo el VIH negativo.</p>
      <p>Se utilizaron como criterios de exclusi&#243;n la presencia de enfermedad arterial coronaria, cerebrovascular o vascular perif&#233;rica, la utilizaci&#243;n de anticoncepcionales, la disfunci&#243;n ventricular (la fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo &lt; 45% por el m&#233;todo de Simpson), la creatinina plasm&#225;tica superior a 1,5 mg y las enfermedades neopl&#225;sicas y de la tiroide.</p>
      <p>Datos de la historia cl&#237;nica del paciente incluyeron edad, sexo, peso (kg), &#237;ndice de masa corporal (IMC), tabaquismo y estadio de la infecci&#243;n del VIH, seg&#250;n el CD4 (linfocitos T Helper).</p>
      <p>
        <bold>Estudio de la funci&#243;n endotelial - protocolo</bold>
      </p>
      <p>La t&#233;cnica utilizada fue la descrita por Celermajer et al. y es recomendada por la <italic>International Brachial Artery Reactivity Task Force</italic><sup>12</sup>.</p>
      <p>El paciente se mantiene en ayuno por ocho horas como m&#237;nimo, debiendo evitarse la pr&#225;ctica de ejercicios f&#237;sicos en la v&#237;spera del examen y el uso de sustancias que interfieran en la vasodilataci&#243;n arterial, como la cafe&#237;na, la vitamina C y el cigarrillo. Para las mujeres, se efect&#250;a la evaluaci&#243;n fuera del per&#237;odo menstrual.</p>
      <p>Se pone al paciente en la posici&#243;n supina, con el brazo confortablemente apoyado en un soporte apropiado. Entonces, la imagen de la arteria braquial se obtiene arriba de la fosa antecubital en un plano longitudinal. La sala de examen se mantiene en una temperatura de 21 grados y en silencio.</p>
      <p>El examen se realiz&#243; con un aparato de ecocardiograf&#237;a (VIVID 3), de GE, equipado con <italic>software</italic> de ultrasonido vascular bidimensional, doppler color y espectral, transductor vascular lineal de alta frecuencia (7-12 MHZ) y monitor interno de electrocardiograma, que registra el trazado de ECG en una derivaci&#243;n.</p>
      <p>Para la evaluaci&#243;n de la vasodilataci&#243;n endotelio dependiente, en el antebrazo del paciente, se puso un esfigmoman&#243;metro, que es insuflado con aire hasta 50 mmHg de la presi&#243;n sist&#243;lica encontrada. Tras ello, se desinfla el manguito (cinco minutos), permitiendo que ocurra isquemia y, por consecuencia, vasodilataci&#243;n por un mecanismo de autorregulaci&#243;n e hiperemia reactiva.</p>
      <p>El flujo de la arteria braquial se registr&#243; por el doppler color, continuamente del 30s al 90s tras desinflar el manguito. Despu&#233;s del registro por hiperemia reactiva, el paciente sigue en reposo por un per&#237;odo de diez minutos. Acto seguido, se inicia la evaluaci&#243;n mediante el mecanismo de vasodilataci&#243;n endotelio independiente.</p>
      <p>La evaluaci&#243;n endotelio independiente se caracteriza por la administraci&#243;n de nitroglicerina spray (0,4 mg) SL. Aguardamos, entonces, tres minutos, que es el tiempo necesario para que ocurra la vasodilataci&#243;n. Tras ese per&#237;odo, el flujo de la arteria braquial se registra por el doppler color. La utilizaci&#243;n de la nitroglicerina est&#225; contraindicado a pacientes hipotensos y bradic&#225;rdicos.</p>
      <p>El di&#225;metro de la arteria braquial se midi&#243; por imagen longitudinal del vaso, calcul&#225;ndose la distancia entre la &#237;ntima proximal y distal en la di&#225;stole. Debido a la gran variabilidad en la medida del di&#225;metro intimal, se elige un &#250;nico punto de reparaci&#243;n, y se efect&#250;an las mediciones en cinco ciclos cardiacos. Esas mediciones se llevaron a cabo siguiendo el ciclo cardiaco y utilizando el trazado del electrocardiograma durante la adquisici&#243;n de las im&#225;genes. La onda R identifica el fin de la di&#225;stole, y el pico de la onda T, el fin de la s&#237;stole.</p>
      <p>La DILA se calcul&#243; como el porcentaje de aumento del di&#225;metro postoclusi&#243;n de la arteria braquial (DPOAB) con relaci&#243;n a sus valores basales. DBAB</p>
      <p><bold>C&#225;lculo de la DILA</bold>: (DPOAB - DBAB) / DBAB x 100%</p>
      <p>DBAB - di&#225;metro basal de la arteria braquial</p>
      <p>Valores superiores al 10% de variaci&#243;n en la dilataci&#243;n de la arteria braquial con relaci&#243;n al basal se consideraron como normales.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Para la verificaci&#243;n de significancia estad&#237;stica en las variables continuas (num&#233;ricas) entre dos subgrupos, se utiliz&#243; la prueba t de Student para muestras independientes o la prueba de Mann-Whitney (no param&#233;trica). Para la comparaci&#243;n de variables categ&#243;ricas (cualitativas), se aplic&#243; la prueba de chi-cuadrado (X&#178;) o la prueba exacta de Fisher.</p>
      <p>
        <graphic xlink:href=""/>
      </p>
      <p>El an&#225;lisis del comportamiento de las mediciones de la reactividad braquial a lo largo del tiempo (tres mediciones), separadas por subgrupos, se realiz&#243; por la varianza (ANOVA) para mediciones repetidas. La prueba de comparaciones m&#250;ltiples de Bonferroni (ajustado para mediciones repetidas) se aplic&#243; para identificar cuales los momentos que difieren entre si. Para verificar si el comportamiento se distingue entre los subgrupos a lo largo del tiempo, se llev&#243; a cabo el an&#225;lisis de varianza para mediciones repetidas con un factor.</p>
      <p>El coeficiente de correlaci&#243;n de Spearman se utiliz&#243; para medir el grado de asociaci&#243;n entre el delta relativo con el perfil metab&#243;lico; y el an&#225;lisis de regresi&#243;n lineal m&#250;ltiple se llev&#243; a cabo para verificar, simult&#225;neamente, la influencia de los datos cl&#237;nicos y metab&#243;licos sobre el delta relativo de la reactividad braquial por el vasodilatador.</p>
      <p>Se utilizaron m&#233;todos no param&#233;tricos, una vez que algunas variables (TG y deltas relativos) no presentaron distribuci&#243;n normal (distribuci&#243;n Gaussiana) debido a la dispersi&#243;n de los datos o a la falta de simetr&#237;a de la distribuci&#243;n.</p>
      <p>El criterio de determinaci&#243;n de significancia adoptado fue el nivel del 5%. El an&#225;lisis estad&#237;stico se proces&#243; por el software SAS 6.04 (SAS Institute, Inc., Cary, North Carolina).</p>
      <p>
        <bold>&#201;tica</bold>
      </p>
      <p>El comit&#233; de &#233;tica en investigaci&#243;n de la Facultad de Medicina de la Universidad Federal Fluminense aprob&#243; la investigaci&#243;n. Para la recolecci&#243;n de los datos, los pacientes fueron sometidos a un formulario de consentimiento informado.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Se seleccionaron a 27 pacientes VIH positivo, con edad promedio de 41,6 a&#241;os (+/- 8,5), provenientes del ambulatorio de SIDA de la asignatura de enfermedades infecto parasitarias de la Facultad de Medicina de la Universidad Federal Fluminense. Teniendo en cuenta este grupo, 15 pacientes (55,6%) hicieron uso de inhibidores de la proteasa.</p>
      <p>Un grupo de 16 pacientes (37,2%), con edad promedio de 43,8 a&#241;os (+/- 4,3), conform&#243; el grupo control.</p>
      <p>Las variables demogr&#225;ficas y cl&#237;nico-laboratoriales est&#225;n detalladas en las <xref ref-type="table" rid="t1-body3">Tablas 1</xref> y <xref ref-type="table" rid="t2-body3">2</xref>.</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href=""/>
      </table-wrap>
      <table-wrap id="t2-body3">
        <graphic xlink:href=""/>
      </table-wrap>
      <p>No hubo diferencia significativa con relaci&#243;n a la edad y al sexo en los grupos VIH positivo y negativo (p = 0,27).</p>
      <p>Variables continuas como cintura abdominal (CA) y HDL-c fueron significativamente menores en el grupo VIH positivo con p = 0,010 y p = 0,050, respectivamente.</p>
      <p>Los pacientes VIH negativo con HAS (93,8% versus 14,8%; p &lt; 0,0001) presentaron niveles pres&#243;ricos m&#225;s elevados que los VIH positivo.</p>
      <p>El TG fue la variable metab&#243;lica predominante en el subgrupo de pacientes VIH positivo y en uso de IP, con p = 0,004 y p = 0,009, con relaci&#243;n a los VIH negativo y sin uso de IP.</p>
      <p>La <xref ref-type="table" rid="t3-body3">Tabla 3</xref> detalla los resultados del estudio de ultrasonido de la arteria braquial.</p>
      <p content-type="asset">
        <table-wrap id="t3-body3">
          <graphic xlink:href=""/>
        </table-wrap>
      </p>
      <p>Mediante el an&#225;lisis de varianza para mediciones repetidas, se evalu&#243; la reactividad braquial por la hiperemia reactiva y vasodilatador en pacientes VIH positivo y negativo en tres momentos (basal, 60s y 90s). Se observ&#243; que existe aumento significativo en la reactividad braquial por la hiperemia reactiva en el subgrupo VIH positivo (p = 0,033) y negativo (p = 0,014) hasta los 60s. No hubo significancia estad&#237;stica a los 90s para los pacientes VIH positivo.</p>
      <p>El an&#225;lisis endotelio independiente (uso de vasodilatador) present&#243; incremento significativo en la reactividad braquial en ambos subgrupos positivo y negativo, con p = 0,0001 y p = 0,0001, respectivamente.</p>
      <p>
        <graphic xlink:href=""/>
      </p>
      <p>Bas&#225;ndose a&#250;n en el an&#225;lisis de varianza, se compar&#243; el subgrupo de pacientes en uso o no de IP a los 60s y 90s de la reactividad braquial. Se observ&#243; que existe un incremento significativo por hiperemia reactiva en el subgrupo con uso de IP (p = 0,038) s&#243;lo a los 60s, no habiendo significancia estad&#237;stica en la medici&#243;n a los 90s.</p>
      <p>Con el uso de nitrato SL, se observ&#243; un incremento significativo de la reactividad braquial en los subgrupos con y sin IP, con p = 0,016 y p = 0,0001, respectivamente.</p>
      <p>Pese a que se observe un aumento significativo en las mediciones de la reactividad braquial (hiperemia reactiva y vasodilatador), principalmente del basal para 60s, tanto en el subgrupo VIH positivo como en el uso de IP, ese aumento es diferenciado. Es decir, el subgrupo VIH positivo o con el uso de IP present&#243; aumento por el vasodilatador significativamente menor que el subgrupo VIH negativo o sin IP.</p>
      <p>Bas&#225;ndose en el an&#225;lisis del delta relativo (%) de la reactividad braquial seg&#250;n el VIH y el IP, se observ&#243; que a los 60s tanto el grupo VIH positivo como el que utiliz&#243; IP presentaron delta relativo por el uso del vasodilatador significativamente menor que el grupo VIH negativo y el sin uso de IP, con p = 0,020 y p = 0,034, respectivamente.</p>
      <p>El delta relativo por la hiperemia reactiva no present&#243; significancia estad&#237;stica en cualquier subgrupo.</p>
      <p>Las <xref ref-type="table" rid="t4-body3">tablas 4</xref> y <xref ref-type="table" rid="t5-body3">5</xref> evidencian el an&#225;lisis del delta relativo de la reactividad braquial, seg&#250;n el VIH y el inhibidor de proteasa, respectivamente.</p>
      <p content-type="asset">
        <table-wrap id="t4-body3">
          <graphic xlink:href=""/>
        </table-wrap>
      </p>
      <p content-type="asset">
        <table-wrap id="t5-body3">
          <graphic xlink:href=""/>
        </table-wrap>
      </p>
      <p>Variables como sexo, &#237;ndice de masa corporal (IMC), cintura abdominal (CA), glucemia, colesterol total (CT), HDL-c, LDL-c e TG no revelaron significancia estad&#237;stica con relaci&#243;n a la reactividad braquial.</p>
      <p>El an&#225;lisis de regresi&#243;n lineal m&#250;ltiple observ&#243; que s&#243;lo el IP disminuy&#243; el delta relativo en los pacientes VIH positivo, por el vasodilatador a los 60 y 90 segundos, con p = 0,032 y p = 0,010, respectivamente.</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Este estudio revel&#243; que pacientes infectados con VIH en uso de HAART, incluyendo IP, hay m&#225;s de dos a&#241;os presentaron disfunci&#243;n endotelial comparado al grupo sin uso de IP y al grupo control no infectado.</p>
      <p>La principal contribuci&#243;n de estos resultados, en cuanto a los estudios previos, es la demostraci&#243;n del compromiso de la respuesta vasodilatadora endotelio independiente en los pacientes VIH positivo en uso de IP.</p>
      <p>Estudios previos<sup>12</sup> han evaluado la funci&#243;n endotelial en pacientes con VIH mediante la t&#233;cnica de la DILA y correlacionado con la probabilidad de desarrollo de enfermedad arterial coronaria. La DILA es una t&#233;cnica no invasiva, exacta y reproductible, es adem&#225;s dependiente de caracter&#237;sticas operacionales relacionadas a la frecuencia del ultrasonido y del entrenamiento t&#233;cnico.</p>
      <p>La disfunci&#243;n endotelial por hiperemia reactiva (endotelio dependiente) y por el uso de nitroglicerina (endotelio independiente) se analiz&#243; por el estudio de la arteria braquial en momentos diferentes de dilataci&#243;n (60s y 90s). Seg&#250;n el protocolo validado<sup>12</sup>, el pico de liberaci&#243;n del oxido n&#237;trico (NO) y de la dilataci&#243;n de la arteria ocurren en este per&#237;odo.</p>
      <p>Nuestro estudio evidenci&#243; que, tanto en el subgrupo de pacientes VIH positivo en cuanto de aquellos en uso de IP, hubo un incremento de la dilataci&#243;n de la arteria braquial por hiperemia reactiva, no habiendo diferencia respecto al subgrupo VIH negativo y sin uso de IP.</p>
      <p>Nolan et al.<sup>13</sup> no encontraron diferencia en la funci&#243;n endotelial cuando compararon el flujo de la arteria braquial en 24 pacientes VIH positivo tratados con IP y 24 pacientes no infectados del grupo control<sup>13</sup>.</p>
      <p>Stein et al.<sup>14</sup> mostraron disminuci&#243;n de la dilataci&#243;n de la arteria braquial en pacientes VIH positivo en uso de IP comparando con pacientes VIH positivo sin uso de IP<sup>14</sup>.</p>
      <p>La vasodilataci&#243;n endotelio independiente realizada mediante el uso de NO ex&#243;geno se relaciona a la funci&#243;n del m&#250;sculo liso. En nuestro estudio, solamente el IP fue significativo para influenciar el delta relativo por el vasodilatador a los 60 y 90 segundos.</p>
      <p>Un estudio evalu&#243; a 800 pacientes asintom&#225;ticos sin VIH y con factores de riesgo para enfermedad cardiovascular, mediante uso de la nitroglicerina ex&#243;gena. Se concluy&#243; que la respuesta reducida al uso de nitroglicerina se correlacion&#243; a la edad aumentada, al incremento del colesterol total, a la historia de <italic>diabetes mellitus</italic> y al tabaquismo<sup>15</sup>.</p>
      <p>Takase et al.<sup>16</sup> analizaron la interacci&#243;n entre HAS y DM en la disfunci&#243;n endotelio independiente y separaron cuatro grupos, siendo DM tipo 2, HAS, HAS/DM y control. Los resultados mostraron que la vasodilataci&#243;n inducida por la nitroglicerina se reduzco en el grupo de pacientes hipertensos y diab&#233;ticos comparado con el grupo control (p &lt; 0,001), mostrando que la interacci&#243;n entre DM ye HAS empeoraron el endotelio vascular, as&#237; como el m&#250;sculo liso responsable de la vasodilataci&#243;n endotelio independiente<sup>16</sup>.</p>
      <p>El mecanismo de disfunci&#243;n endotelial es explicado tanto por la acci&#243;n del virus como por el uso de HAART. Shankar et al. revelaron disminuci&#243;n de la dilataci&#243;n de la arteria braquial en ni&#241;os VIH positivas sin uso de antirretrovirales<sup>17</sup>. El virus act&#250;a en el endotelio por intermedio de la glicoprote&#237;na 120 (Gp120), conllevando la producci&#243;n de mol&#233;culas de adhesi&#243;n (ICAM-1), estados protromb&#243;ticos, TNF alfa e interleuquina 6 (IL-6).</p>
      <p>Aunque los IPs reduzcan el &#243;xido n&#237;trico sintetasa endotelial (eNOS), conllevando la disminuci&#243;n de la producci&#243;n de &#243;xido n&#237;trico, las especies reactivas de ox&#237;geno (ROS) contribuyen para la disfunci&#243;n endotelial, conllevando la inflamaci&#243;n, el da&#241;o celular y la apoptosis de las c&#233;lulas endoteliales. Los IPs inducen la formaci&#243;n de ROS<sup>18</sup>. Mondal et al.<sup>19</sup> evidenciaron la presencia de ROS en las c&#233;lulas endoteliales de la arteria aorta de pacientes en uso de Zidovudina y Efavirenz<sup>19</sup>.</p>
      <p>Los IPs tambi&#233;n conllevan la disfunci&#243;n del DNA mitocondrial, contribuyendo al aumento del estr&#233;s oxidativo. Cote et al. mostraron el primer caso de disfunci&#243;n mitocondrial en pacientes VIH positivo en uso de IP y con s&#237;ntomas de hiperlactatemia<sup>20</sup>.</p>
      <p>Uno de los principales mecanismos que explica la disfunci&#243;n endotelial inducida por el IP est&#225; relacionado a la activaci&#243;n de prote&#237;nas kinasas (MAPKs) por especies reactivas de ox&#237;geno. Los IPs activan diferentes tipos de MAPKs en c&#233;lulas distintas<sup>21</sup>.</p>
      <p>Las ROS tambi&#233;n est&#225;n presentes en las c&#233;lulas del m&#250;sculo liso, responsable por la vasodilataci&#243;n endotelio independiente, conllevando a la disfunci&#243;n endotelial por el uso de NTG en pacientes que usan IP. Chai et al.<sup>22,23</sup> demostraron la presencia de anion super&#243;xido en las c&#233;lulas endoteliales del m&#250;sculo liso de pacientes tratados con IP<sup>22,23</sup>. Kim et al.<sup>24</sup> evidenciaron que prote&#237;nas virales afectan la proliferaci&#243;n de las c&#233;lulas endoteliales del m&#250;sculo liso, representando el mayor evento en la formaci&#243;n de la lesi&#243;n vascular<sup>24</sup>.</p>
      <p>Estudios preliminares revelan que antioxidantes como la Ginsenoside y el Curcumin podr&#225;n reverter la disfunci&#243;n endotelial causada por los IPs, disminuyendo las ROS<sup>25</sup>.</p>
      <p>La principal limitaci&#243;n de nuestro estudio fue la presencia de hipertensi&#243;n arterial en el grupo de voluntarios, sin embargo no impidi&#243; la confirmaci&#243;n de nuestros hallazgos con relaci&#243;n a la disfunci&#243;n vascular endotelio independiente.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Los pacientes VIH positivo en uso de IP presentan disfunci&#243;n endotelio independiente cuando comparados a pacientes VIH positivo que no est&#225;n en tratamiento con IP y a un grupo control.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio fue parcialmente financiado por la CAPES.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este artigo forma parte de tesis de Maestr&#237;a de Hamilton Nenrod Pereira Teixeira, por la Universidad Federal Fluminense.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
